CellWell record HH-145249
Kang Ru Plus reverses osimertinib resistance in lung adenocarcinoma via suppression of EGFR/PI3K/AKT signaling
Thomas G Mhone; Wei-Wen Kuo; Chih-Ying Chi; Chia-Hua Kuo; Tsung-Jung Ho; Yu-Ling Wu; Yueh-Min Lin; Ming-Cheng Chen; Chih-Yang Huang; Shinn-Zong Lin
2026
In plain language
Kang Ru Plus, a multi-herb formulation, enhanced osimertinib sensitivity in resistant lung adenocarcinoma by suppressing EGFR phosphorylation and downstream PI3K/AKT/ERK signaling.
- Evidence
- Emerging
- Design
- Primary research (design unspecified)
Cite this record: https://thecellwell.org/studies/HH-145249
Produced by the CellWell Research Engine, custom software owned and operated by CellWell and The Holistic Hub. All rights reserved. This analysis, its indexing and its evidence classifications are proprietary. Any use, republication or onward sharing must credit CellWell Research Engine (thecellwell.org) as the source.
This is an educational research library, not medical advice. Nothing here may be used to diagnose, treat, cure, or prevent any disease. Always consult a qualified professional.